Canada: For Your Phase 3 Global Trial Expansion
Oncology continues to be the largest and fastest growing therapeutic area in the clinical trials market, and a market dominated…
Doubly Nimble: why you should open global P1 clinical trials in Canada on Day 1
With agility increasingly becoming the most important global driver of success, it’s worth noting that Canadian oncology research center Phase…
What’s Best for Your Phase III Clinical Study?
It’s worth your time to consider whether or not the commonly held belief that using a larger CRO for your…
Troubleshooting Underperforming Sites – Best Practices
It’s no surprise that an underperforming site can cause significant delays in meeting important accrual targets, data timelines, or study…
Special Report: What’s in Store for Global Clinical Trials in 2022 and Beyond?
The Global Clinical Trials Market was valued at $44.3B USD in 2020, and by 2028 is expected to reach $69.3B…
Prime Location for Global Clinical Studies?
Canada is considered one of the most attractive places to live in the world, with a high quality of life,…
What & Where: the ‘Next Normal’ in Oncology Clinical Research
Developing oncology compounds is a constantly evolving process, and never more so than now. Pre-pandemic oncology was both the largest…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…
Let Canada Contribute to Your Basket Trial Success
With the emergence of basket trials in the early-phase oncology setting, clinical research teams are faced with challenges of enrollment…